Full-Time

Senior Director

Operations

Posted on 1/30/2025

Cellares

Cellares

201-500 employees

Develops and manufactures cell therapies

Compensation Overview

$170k - $220k/yr

Expert

Bridgewater Township, NJ, USA

Category
Quality Control & Compliance
Supply Chain Management
Operations & Logistics
Requirements
  • Bachelor's degree in science, engineering, or a related field is required
  • A minimum of 10 years of operations experience within a cGMP environment in the biotech/biopharma industry with a minimum of 5 years of leadership experience. Cell/Gene Therapy and CDMO experience preferred
  • Work effectively with the US FDA and other regulatory agencies. Substantial knowledge of Quality Systems, GMP, FDA, GAMP, ISO, and other applicable standards
  • Demonstrated experience in managing commercial manufacturing operations
  • Demonstrated startup experience or leading organizations through dramatic growth
  • Ability to build strong partnerships and effectively integrate with external collaborators to drive projects/programs forward in a matrixed environment
  • Must be able to manage shifting priorities to meet critical deadlines in a fast-paced and dynamic, growing environment while providing clear direction to team members
  • History of developing and building cohesive, high-performing teams with a strong sense of mission, providing training and mentoring to build sufficient management depth throughout the organization and ensure strong succession planning
  • Strong analytical, problem-solving solving, and critical thinking skills and the ability to lead as a change agent to promote flexibility, creativity, and accountability
  • Excellent teamwork and interpersonal skills with the ability to influence and build strong working relationships at all levels within the organization
  • cGMP manufacturing experience, preferably cell/gene therapy, with experience in tech transfer, process validation, project management, and change management
  • Experience with Operational Excellence and/or Lean Manufacturing
  • Excellent organizational and communication skills
  • Self-motivated and passionate about advancing the field of cell therapy
  • Self-awareness, integrity, authenticity, and a growth mindset
Responsibilities
  • Lead, direct, coach, and develop an effective Operations team responsible for daily clinical and commercial production of autologous and allogeneic cell therapy products while ensuring safe and compliant operations according to cGMP requirements
  • Provide technical and managerial leadership by effectively interfacing and collaborating with key stakeholders and functions across the organization to successfully manufacture and disposition products to patients in a timely manner
  • Oversight of production metrics, including Safety, Quality, Compliance, Cost, Delivery, and People within the facility to ensure high-quality and compliant product supply
  • Oversee the hiring, development, and performance management of staff within operations
  • Lead facility operating review meetings and own various department projects to drive continuous improvements and efficiencies within operations
  • Establish critical KPIs, monitor progress, and keep critical stakeholders informed of progress
  • Lead and actively participate in all regulatory and internal audits of the facility
  • Work closely with other functional areas to develop and execute the strategic plan for the manufacturing site
  • Establish key stakeholder relationships with internal and external stakeholders
Desired Qualifications
  • Cell/Gene Therapy and CDMO experience preferred

Cellares develops and manufactures cell therapies, focusing on biotechnology. The company operates as an Integrated Development and Manufacturing Organization (IDMO), which means it combines the development and manufacturing processes of cell therapies in one facility. This approach is different from traditional Contract Development and Manufacturing Organizations (CDMOs) that keep these processes separate. Cellares utilizes its proprietary "Smart Factory" technology, featuring an automated single-use cartridge system that significantly boosts productivity, reduces costs, and lowers process failure rates. The company serves a variety of clients, including those in preclinical, clinical, and commercial stages, and has partnered with major pharmaceutical companies to enhance the manufacturing of CAR-T cell therapies. Cellares aims to provide efficient and cost-effective manufacturing solutions for cell therapies, making it a competitive choice in the biotechnology sector.

Company Size

201-500

Company Stage

Series C

Total Funding

$355M

Headquarters

South San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Bristol Myers Squibb secures $380M for CAR T cell therapy manufacturing.
  • Ossama Eissa's appointment as COO strengthens Cellares' global expansion and operational efficiency.
  • Sony partnership enhances Cell Shuttle with advanced flow cytometry, improving precision and efficiency.

What critics are saying

  • Emerging competition from bluebird bio may increase market pressure on Cellares.
  • Rapid Smart Factory expansion could strain resources and affect quality control.
  • Over-reliance on Bristol Myers Squibb partnership poses risk if dynamics change.

What makes Cellares unique

  • Cellares' Cell Shuttle offers 10x scalability over manual cell therapy manufacturing processes.
  • The Smart Factory technology integrates development and manufacturing, unlike traditional CDMOs.
  • Cell Q automates QC for up to 6,000 batches, reducing manual labor and costs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

3%

2 year growth

6%
RegMedNet
Apr 3rd, 2025
Cell therapy weekly: regulatory boost for automated cell therapy production platform

bluebird bio announced on 21 February 2025 that it had entered into a definitive agreement to be acquired global investment firms Carlyle (DC, USA) and SK Capital (NY, USA) for US$3.00 per share in cash, plus a contingent value right of $6.84 per share if certain sales targets are met.

ROI-NJ
Nov 13th, 2024
Cellares appoints former Novartis, Lonza and Legend Biopharma exec as COO

Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.

ROI-NJ
Nov 13th, 2024
Cellares Appoints Former Novartis, Lonza And Legend Biopharma Exec As Coo

Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.Eissa’s extensive experience will support the expansion of Cellares’ Smart Factory network in the United States, Europe, Japan and other international markets, addressing the challenges of scalability, cost, and quality that have long hindered patient access. Through these advancements, Cellares will work to ensure that life-saving treatments are accessible for oncology and autoimmune patients globally.This appointment strengthens the Cellares leadership team in a time of rapid global expansion of the company’s IDMO manufacturing services, in response to the growing global demand for cell therapy manufacturing capacity.Eissa brings more than 20 years of experience in pharmaceutical and biotech manufacturing.He formerly served as vice president and general manager at Legend Biotech, where he led the Raritan production site through the global launch of Carvykti, a CAR-T cell therapy.At Lonza Biologics, Eissa managed Global Strategic Projects, contributing significantly to the Cell and Gene Technologies Business Unit by boosting manufacturing efficiency and driving commercial scale-up. He also oversaw U.S. manufacturing operations at Novartis, scaling production and supporting regulatory approval for Kymriah, the first FDA-approved CAR-T cell therapy.“Joining Cellares is an opportunity to address one of the biggest challenges in healthcare today: making cell therapies accessible to all of those who need them,” Eissa said. “The mission aligns closely with my experience in scaling complex manufacturing systems to benefit patients directly. I’ve witnessed the profound impact these treatments have, and I’m committed to ensuring that we reach more patients, especially those facing cancer and autoimmune diseases, with the reliability and speed they deserve.”

BioProcess International
Sep 12th, 2024
Cellares and Sony partner to automate cell therapy manufacturing

Self-acclaimed integrated development and manufacturing organization (IDMO) Cellares has partnered with Sony Corporation, a technology firm focused on the field of flow cytometry, to integrate advanced flow cytometry-based cell analysis and sorting solutions into the Cellares Cell Shuttle platform.

Contract Pharma
Sep 3rd, 2024
Cellares Appoints CFO and General Counsel

Cellares, a leader in cell therapy manufacturing and an Integrated Development and Manufacturing Organization (IDMO), has appointed Justin McAnear as Chief Financial Officer (CFO) and Jonathan Butler as General Counsel and Corporate Secretary (GC).

INACTIVE